Intech Investment Management LLC Sells 42,229 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Intech Investment Management LLC reduced its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 9.5% during the fourth quarter, Holdings Channel reports. The firm owned 400,108 shares of the company’s stock after selling 42,229 shares during the period. Intech Investment Management LLC’s holdings in Teva Pharmaceutical Industries were worth $12,487,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in TEVA. Allworth Financial LP raised its position in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the period. Grove Bank & Trust raised its position in Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after acquiring an additional 750 shares during the period. EverSource Wealth Advisors LLC raised its position in Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after acquiring an additional 345 shares during the period. Global Retirement Partners LLC raised its position in Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after acquiring an additional 292 shares during the period. Finally, 1620 Investment Advisors Inc. raised its position in Teva Pharmaceutical Industries by 1,823.2% in the fourth quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock worth $49,000 after acquiring an additional 1,495 shares during the period. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $35.32 on Friday. The company has a market capitalization of $40.61 billion, a price-to-earnings ratio of 26.56, a PEG ratio of 3.34 and a beta of 0.86. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The firm has a 50-day moving average price of $32.35 and a 200-day moving average price of $31.33. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. Equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on TEVA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. The Goldman Sachs Group lifted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Finally, Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $41.78.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the transaction, the executive vice president owned 63,647 shares of the company’s stock, valued at approximately $2,247,375.57. The trade was a 25.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard Daniell sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the sale, the executive vice president directly owned 55,755 shares in the company, valued at $1,973,727. This trade represents a 34.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 934,459 shares of company stock valued at $31,122,931. 0.54% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.